Company / Current Liabilities
Astria Therapeutics, Inc. Current Liabilities History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$19.1M
FY2024
5-year range
$5.2M / $19.1M
FY2020-FY2024
Trend
+65.6%
vs FY2023
Sector context
#191 of 213
Health Care
What the data says
Among 213 Health Care companies, Astria Therapeutics, Inc. is in the top 10% for current liabilities. Current Liabilities has increased for 3 consecutive years, from $5M in FY2021 to $19M in FY2024.
Based on SEC 10-K filings.
$19M in FY2024 with a 5-year CAGR of +30.6%.
Increased from $9M to $19M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +54.3%
- 5-Year CAGR
- +30.6%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 213This company $19.1M Sector average $1.6B
▼
-98.8% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s current liabilities has grown for 3 consecutive years.
- 5-year CAGR of +30.6%, indicating consistent growth.
- In FY2024, current liabilities increased 65.6% year-over-year.
- Ranks #191 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $19.1M | +65.6% |
| FY2023 | $11.6M | +27.5% |
| FY2022 | $9.1M | +74.1% |
| FY2021 | $5.2M | -18.6% |
| FY2020 | $6.4M | +27.0% |
| FY2019 | $5.0M | +20.6% |
| FY2018 | $4.2M | -30.7% |
| FY2017 | $6.0M | -27.7% |
| FY2016 | $8.3M | +7.0% |
| FY2015 | $7.8M | +83.7% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026